BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rintz E, Higuchi T, Kobayashi H, Galileo DS, Wegrzyn G, Tomatsu S. Promoter considerations in the design of lentiviral vectors for use in treating lysosomal storage diseases. Mol Ther Methods Clin Dev 2022;24:71-87. [PMID: 34977274 DOI: 10.1016/j.omtm.2021.11.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Leal AF, Alméciga-Díaz CJ. Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA. Gene Ther 2023;30:107-14. [PMID: 35581402 DOI: 10.1038/s41434-022-00344-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
2 Syzdykova L, Zauatbayeva G, Keyer V, Ramanculov Y, Arsienko R, Shustov AV. Process for production of chimeric antigen receptor-transducing lentivirus particles using infection with replicon particles containing self-replicating RNAs. Biochemical Engineering Journal 2023. [DOI: 10.1016/j.bej.2023.108814] [Reference Citation Analysis]
3 Leal AF, Benincore-Flórez E, Rintz E, Herreño-Pachón AM, Celik B, Ago Y, Alméciga-Díaz CJ, Tomatsu S. Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets. Int J Mol Sci 2022;24. [PMID: 36613919 DOI: 10.3390/ijms24010477] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Mashima R, Nakanishi M. Mammalian Sulfatases: Biochemistry, Disease Manifestation, and Therapy. IJMS 2022;23:8153. [DOI: 10.3390/ijms23158153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]